

AWARD NUMBER: W81XWH-20-1-0209

TITLE: HOXB13-Dependent Metastasis Suppression of Prostate Cancer by
Proteoglycan Signaling

PRINCIPAL INVESTIGATOR: Donald J. Vander Griend, Ph.D.

CONTRACTING ORGANIZATION: The University of Illinois, Chicago, IL

REPORT DATE: October 2022

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2022		2. REPORT TYPE Annual		3. DATES COVERED 01Sep2021-31Aug2022	
4. TITLE AND SUBTITLE HOXB13-Dependent Metastasis Suppression of Prostate Cancer by Proteoglycan Signaling				5a. CONTRACT NUMBER W81XWH-20-1-0209	
				5b. GRANT NUMBER PC 190812	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Donald Vander Griend, Ph.D. E-Mail: dvanderg@uic.edu				5d. PROJECT NUMBER 0011470319	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Illinois Office of Business and Financial Service 809 S. Marshfield Room 520 Chicago, IL 60612-4305				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) DOD PCRP	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT HOXB13 is the predominant HOX gene expressed in prostate epithelial cells, and germline mutations in HOXB13 are strongly associated with increased prostate cancer incidence. Significant research has focused on the role of HOXB13 as it relates to Androgen Receptor (AR) signaling and cancer cell responses to AR-targeted therapies. Our laboratory recently determined that the HOX co-factors MEIS1 and MEIS2 are novel tumor suppressor genes in prostate cancer, are the predominant HOXB13 binding partner in non-malignant prostate epithelial cells, and interfere with oncogenic AR/HOXB13 transcription. MEIS proteins function as critical transcriptional co-factors during development and within adult tissues to bind HOX proteins and specify HOX gene targeting. In fact, the majority of germline <i>HOXB13</i> mutations are located within the MEIS-interacting domain, emphasizing the importance of MEIS/HOX interactions in prostate tumor biology. Our data supports a critical tumor-suppressive and anti-androgen role for MEIS proteins in prostate cancer, and while HOXB13 mutations are uncommon, we have shown that MEIS proteins are frequently down-regulated in prostate tumors. However, there remain significant gaps in our understanding of the mechanistic function of MEIS proteins to block metastatic progression, and the impact of HOXB13 mutations on MEIS binding and gene regulation; filling such knowledge gaps has a high potential to functionally implicate new biomarkers to predict cancer progression and new targets to therapeutically block prostate cancer metastasis.					
15. SUBJECT TERMS Prostate Cancer, MEIS proteins, HOXB13, Decorin, metastasis, Androgen Receptor					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	6
5. Changes/Problems	6
6. Products	6
7. Participants & Other Collaborating Organizations	6
8. Special Reporting Requirements	6
9. Appendices	7

1. Introduction

HOXB13 is the predominant HOX gene expressed in prostate epithelial cells, and germline mutations in HOXB13 are strongly associated with increased prostate cancer incidence. Significant research has focused on the role of HOXB13 as it relates to Androgen Receptor (AR) signaling and cancer cell responses to AR-targeted therapies. Our laboratory recently determined that the HOX co-factors MEIS1 and MEIS2 are novel tumor suppressor genes in prostate cancer, are the predominant HOXB13 binding partner in non-malignant prostate epithelial cells, and interfere with oncogenic AR/HOXB13 transcription. MEIS proteins function as critical transcriptional co-factors during development and within adult tissues to bind HOX proteins and specify HOX gene targeting. In fact, the majority of germline *HOXB13* mutations are located within the MEIS-interacting domain, emphasizing the importance of MEIS/HOX interactions in prostate tumor biology. Our data supports a critical tumor-suppressive and anti-androgen role for MEIS proteins in prostate cancer, and while HOXB13 mutations are uncommon, we have shown that MEIS proteins are frequently down-regulated in prostate tumors. This proposal builds upon work demonstrating an essential role for MEIS proteins as critical HOXB13-dependent suppressors of prostate tumor metastasis, cell proliferation, and oncogenic AR activity. However, there remain significant gaps in our understanding of the mechanistic function of MEIS proteins to block metastatic progression, and the impact of HOXB13 mutations on MEIS binding and gene regulation; filling such knowledge gaps has a high potential to functionally implicate new biomarkers to predict cancer progression and new targets to therapeutically block prostate cancer metastasis.

The goal of this project is to understand how MEIS proteins suppress prostate tumor metastasis in order to develop functional biomarkers and pharmacologic strategies to prevent and treat prostate cancer progression. The objective of this proposal is to define how MEIS proteins suppress metastasis, how germline *HOXB13* mutations impact MEIS-mediated tumor suppression, and whether MEIS re-expression can block AR-V7 function in Enzalutamide-resistant prostate cancer cells. Our **central hypothesis** is that MEIS expression drives prostate tumor indolence via proteoglycan-mediated inhibition of cell proliferation and migration, blocks AR-V7 binding to HOXB13, and that *HOXB13* mutations reduce MEIS-mediated tumor suppression.

Specific Aim 1: To determine the role of MEIS-mediated regulation of proteoglycans in suppressing prostate cancer growth and metastasis.

Specific Aim 2: To elucidate the functional impact of *HOXB13* mutations on MEIS-mediated tumor suppression.

Specific Aim 3: To determine the role of MEIS expression on DCN expression and activity using patient-derived xenograft (PDX) models.

2. Keywords

Prostate Cancer; MEIS1, MEIS2, HOXB13, Decorin, Patient-Derived Xenograft, Androgen Receptor (AR)

3. Accomplishments

Research accomplishments are based upon the outlined Statement of Work. These are as follows:

Major Task 1: Determine the necessity of DCN expression for MEIS-mediated metastasis suppression.

Subtask 1: Obtain IACUC and ACURO regulatory approval for animal work.

Progress: We obtained IACUC and ACURO regulatory approval.

Subtask 2: CRISPR Targeting of DCN and MEIS-re-expression in CWR22Rv1 and LAPC4 cells.

Progress: We designed targeting guide RNAs against DCN, and have targeted the DCN gene CWR22Rv1 and LAPC4 cells using CRISPR-Cas9 editing approaches. We are currently screening clonal lines via western blotting for loss of DCN expression.

Major Task 3: Determine the impact of *HOXB13* mutations on MEIS-mediated growth suppression.

Subtask 1: Creation and validation of HOXB13 mutants using CRISPR-Cas9 targeting.

Progress: We have successfully acquired multiple CWR22Rv1 cells harboring the G84E HOXB13 mutation. This includes a wild-type isogenic clone (**Figure 1A**). These cells were analyzed for HOXB13 protein expression as well (**Figure 1B**). We are currently ectopically-expressing lentiviral MEIS1 in these lines, and plan to evaluate DCN, among other targets.




Figure 1: CRISPR gene targeting to create heterozygous HOXB13 (G84E) mutant prostate cancer cell lines. A) Sequencing data demonstrating heterozygous HOXB13 (G84E) mutations in one allele of CWR22Rv1 cell lines. An isogenic wild-type control was also acquired. B) Western blotting demonstrating HOXB13 protein expression of the G84E clones.

Second, we have ectopically expressed MEIS1 in CWR22Rv1 cells harboring HOXB13(G84E) mutations. These cells (HOXB13-WT+MEIS1 vs. HOXB13(G84E)+MEIS1 x three clones) are being tested for growth and DCN expression. Data thus far supports a model whereby HOXB13(G84E) mutations abrogate MEIS-mediated growth suppression; we are currently undergoing replicate experiments for statistical analysis.

Major Task 4: Elucidate the impact of *HOXB13* mutations on gene regulation.

Subtask 1: qPCR and Western Blotting for DCN.

Progress: We have successfully analyzed both DCN and LUM (Lumicon, a proteoglycan similar to DCN) when MEIS1 is expressed in CWR22Rv1 cells harboring HOXB13(G84E) mutations. In support of our hypothesis, presence of the G84E mutation decreases DCN and LUM expression compared to HOXB13-WT controls (**Figure 2**). We are currently characterizing these lines further, and a gearing up for RNA-Seq and MEIS1 ChIP-Seq.




Figure 2: Presence of HOXB13(G84E) mutations in CWR22Rv1 prostate cancer cells decreases MEIS1-mediated expression of DCN and LUM.

Cells with ectopic expression of MEIS1 in CWR22Rv1 cell harboring wild-type HOXB13 or G84E-mutant HOXB13 were analyzed for induction of the proteoglycans DCN and LUM. This is qPCR data quantifying decreased DCN and LUM expression in HOXB13(G84E)-containing cells compared to HOXB13-WT cells.

Major Task 5: Elucidate the expression of DCN target pathways within MEIS^{High} vs. MEIS^{Low} PDX tumors.

Subtask 1: Complete MTA, obtain, and expand LuCaP PDX tumor xenograft models.

Progress: We have completed the MTA for the PDX tumor models, have received them from our collaborator, and have successfully established them within our own animal facility. These tumors are currently growing and being expanded into additional mice for cryopreservation, analyses, and viral infection.

Subtask 2: All five proposed PDX tumors have been successfully propagated and cryopreserved. We have obtained FFPE blocks and mRNA for further analyses. These tumors have been analyzed for AR, HOXB13, and MEIS1 using qPCR (**Figure 3A**), and IHC (**Figure 3B**).




Figure 3: Expression of AR, HOXB13, and MEIS1 in five LuCaP PDX tumors. A) qPCR data showing variable AR, HOXB13, and relatively low MEIS1 expression in five PDX tumors. B) IHC analysis of AR, AR-V7, HOXB13, and MEIS1 in all five PDX tumors.

4. Impact

The majority of the preliminary data utilized for the grant was published in 2020: VanOpstall C, Perike S, Brechka H, Gillard M, Lamperis S, Zhu B, Brown R, Bhanvadia R, and **Vander Griend DJ**. *MEIS-Mediated Suppression of Prostate Cancer Growth and Metastasis Through HOXB13-Dependent Regulation of Proteoglycans*. *eLife*; June 18, 2020; 9:e53600. doi: 10.7554/eLife.53600.

DCN knockout prostate cancer cell lines will have value to the prostate cancer research community.

The implementation of PDX models in our lab represent new model systems for our team and research community.

The HOXB13 mutant lines will have value to the prostate cancer research community.

5. Changes/Problems

We have encountered no problems or hurdles which require modifications to our Statement of Work. Further, we were fortunate to have initiated our animal and cell-based experiments during COVID-related slowdowns and the need for decreased personnel in the lab.

6. Products

Nothing to report.

7. Participants & Other Collaborating Organizations

Nothing to report.

8. Special Reporting Requirements

Nothing to report.

9. Appendices

VanOpstall C, Perike S, Brechka H, Gillard M, Lamperis S, Zhu B, Brown R, Bhanvadia R, and **Vander Griend DJ**. *MEIS-Mediated Suppression of Prostate Cancer Growth and Metastasis through HOXB13-Dependent Regulation of Proteoglycans*. *eLife*; June 18, 2020; 9:e53600. doi: 10.7554/eLife.53600.
Pubmed URL: <https://pubmed.ncbi.nlm.nih.gov/32553107/>
Manuscript URL: <https://elifesciences.org/articles/53600#info>